Radical cystectomy (RC) may provide a survival advantage to patients with clinically localized node-positive bladder cancer, according to a poster presentation at the ASCO Genitourinary Cancers Symposium 2022.
Among 8460 patients receiving systemic chemotherapy in the 2004-2018 National Cancer Database, investigators identified 3565 (42.1%) who also underwent RC. (Patients with distant metastases, including to non-regional nodes, or treated with radiation were excluded.)
Overall survival rates were comparable at 5 years among the RC and nonsurgical groups: 34.1% vs 36.1%. On multivariate analysis, however, RC was significantly associated with a 19% reduced risk for all-cause mortality, Stuthi Perimbeti, MD, MPH, of Roswell Park Comprehensive Cancer Center in Buffalo, New York, reported on behalf of her team.
Patients with 2 or more comorbidities had significant 1.7-fold increased risks for death compared with those had no comorbidities. Advanced age (70-85 vs 18-35 years), lack of insurance, female sex, Black vs White race, and lower annual income (less than $30,000 vs more than $45,000) were significantly associated with 1.9-, 1.4-, 1.2-, 1.2-, and 1.2-fold increased risks for early mortality, respectively.
Median age at diagnosis was significantly younger in the RC group: 65 vs 68 years.
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Perimbeti S, Jiang C, Deng L, et al. Survival outcomes with radical cystectomy (RC) in localized clinically node-positive bladder cancer (CNBC). Presented at ASCO GU 2022; February 17-19, 2022. Poster 520.